# Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Canonical URL: https://biopharmsignal.com/news/EDIT/editas-medicine-to-host-webinar-announcing-lead-in-vivo-development-candidate-0648a3c5
Ticker: EDIT
Company: Editas Medicine
Source: Editas Medicine
Published: 2025-08-28 20:01 EST
## Summary

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing...

## Article Body
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.

Webinar Presentation Details: The live and archived webcast of the Company’s webinar presentation will be accessible through this webcast link , or through the Events & Presentations page of the “Investors” section of the Company’s website.

A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/ .

About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
## Recent Company News
- 2026-05-28 20:01 EST — [Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-updated-presentation-time-for-upcoming-investor-confer-ef3968d7) — Source: Editas Medicine
- 2026-05-26 13:05 EST — [Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-pricing-of-up-to-319-4-million-public-offering-127eec22) — Source: Editas Medicine
- 2026-05-26 10:15 EST — [Editas Medicine Announces Proposed Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-proposed-public-offering-1685aa73) — Source: Editas Medicine
- 2026-05-26 10:01 EST — [Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress](https://biopharmsignal.com/news/EDIT/editas-medicine-presents-edit-401-preclinical-data-demonstrating-robust-reductio-8f1aef48) — Source: Editas Medicine
- 2026-05-14 10:01 EST — [Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/EDIT/editas-medicine-reports-new-preclinical-data-demonstrating-progress-of-edit-401--a6308965) — Source: Editas Medicine
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)